Novavax Inc (NVAX.O)
27 Feb 2017
* Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S
Nov 9 Novavax Inc said on Wednesday it would cut 30 percent of its global workforce, or 164 jobs, to help fund the testing of its vaccine for a common respiratory virus in the elderly, about two months after failing a late-stage study.
Novavax Inc said on Thursday that its experimental vaccine for a serious infectious respiratory disease failed at the final stage of human testing, sending its stock plunging more than 80 percent.
- Novavax's (NVAX) CEO Stan Erck on Q4 2016 Results - Earnings Call Transcript
- Novavax (NVAX) Presents At 35th Annual J.P. Morgan Healthcare Conference
- Marketplace Roundtable: 2017 Looks Geopolitically Cloudy, With A Chance Of Stronger Growth
- Novavax (NVAX) Presents at 28th Annual Piper Jaffray Healthcare Conference (Transcript)
- Novavax: The Little Engine That Couldn't
- Biotech Forum Daily Digest: Digesting A "Yuge" Week! The FDA Steps On Dynavax's Hopes Once Again. Revisiting Portola Pharmaceuticals